RPL34P21

Across TCGA pan-cancer cohorts, RPL34P21 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL34P21’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RPL34P21 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL34P21 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

HNSC, UCEC, and PRAD are the cancer types where RPL34P21 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL34P21 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.068	.005	5	view →
UCEC	All	IV	+0.610	.012	2	view →
PRAD	All	All	+0.163	.046	2	view →
LUAD	Female	III,IV	−0.175	.030	1	view →
LIHC	Female	II,III,IV	+0.081	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL34P21–HNSC

Open the HNSC breakdown →